Glenn S Kroog

8PUBLICATIONS
88CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 07, 2026
A mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data.

|Jun 12, 2026
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study.

|Apr 01, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.

Shaji Kumar, Katja C Weisel, Paul Spin

|Mar 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Shaji Kumar, Sundar Jagannath, Katja C Weisel

|Feb 27, 2025
Patient preferences for triple-class-exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study.

Sikander Ailawadhi, Timothy J Inocencio, Carol Mansfield

|Oct 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.

Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson

Pageof 2

Frequent Collaborators

4 joint publications

Alexander Breskin

4 joint publications

Christian Hampp

3 joint publications

Sundar Jagannath

3 joint publications

Mostafa Shokoohi